Quantitative Optical Coherence Tomography Angiography Biomarkers in a Treat-and-Extend Dosing Regimen in Neovascular Age-Related Macular Degeneration.
age-related macular degeneration
anti-vascular endothelial growth factor
choroidal neovascularization
optical coherence tomography angiography
treat-and-extend protocol
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
14 02 2020
14 02 2020
Historique:
entrez:
28
7
2020
pubmed:
28
7
2020
medline:
28
7
2020
Statut:
epublish
Résumé
To evaluate the association between quantitative optical coherence tomography angiography (OCT-A) parameters and clinical outcomes in treatment-naïve neovascular age-related macular degeneration (nAMD) patients treated with a treat-and-extend dosing regimen on a 12-month follow-up interval. Observational, prospective study of consecutive patients. The treatment protocol was based on a loading dose of three anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVI) followed by a treat-and-extend regimen. Eyes were evaluated by swept-source OCT-A at baseline, 1 month after the loading dose and at 12 months. A quantitative analysis was issued for fractal dimension (FD), lacunarity index (LAC), blood flow surface area (SA), and vessel density (VD). An association of these parameters with the anatomic response and functional responses, and IVI number at 12 months of follow-up was assessed. A level of significance α = 0.05 was considered. Sixty-four patients were included, 52 of whom (81%) completed the 12-month study protocol. The median number of injections at 12 months was 7 (P Baseline OCT-A may provide useful biomarkers for the treatment burden in nAMD. The application of fractal dimension and automatic blood flow area algorithms to OCT-A data can distinguish patients with distinct treatment burdens in the first year of nAMD.
Identifiants
pubmed: 32714644
doi: 10.1167/tvst.9.3.18
pii: TVST-19-1815
pmc: PMC7351878
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Pagination
18Informations de copyright
Copyright 2020 The Authors.
Déclaration de conflit d'intérêts
Disclosure: D. Cabral, None; F. Coscas, None; T. Pereira, None; C. Français, None; C. Geraldes, None; R. Laiginhas, None; C. Rodrigues, None; A.K. Kashi, None; V. Nogueira, None; M. Falcão, None; A.L. Papoila, None; M. Lupidi, None; G. Coscas, None; S.Y. Cohen, None; E. Souied, None
Références
J Ophthalmol. 2018 Feb 4;2018:3751702
pubmed: 29507810
Transl Vis Sci Technol. 2019 May 2;8(3):7
pubmed: 31110909
Ophthalmic Res. 2015;54(2):57-63
pubmed: 26201877
Am J Ophthalmol. 2014 May;157(5):1013-21
pubmed: 24487050
J Neurosci Methods. 1996 Nov;69(2):123-36
pubmed: 8946315
Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5098-5104
pubmed: 28986595
JAMA. 2004 Apr 21;291(15):1900-1
pubmed: 15108691
Annu Rev Biomed Eng. 2004;6:427-52
pubmed: 15255776
Br J Ophthalmol. 2019 Sep;103(9):1342-1346
pubmed: 30467129
PLoS One. 2017 May 10;12(5):e0177059
pubmed: 28489918
Retina. 2017 Aug;37(8):1492-1498
pubmed: 27997513
Br J Ophthalmol. 2018 Jul 4;:
pubmed: 29973363
Am J Ophthalmol. 2015 Jul;160(1):6-16
pubmed: 25887628
Ophthalmol Ther. 2017 Jun;6(1):79-92
pubmed: 28451952
Semin Ophthalmol. 2011 May;26(3):225-33
pubmed: 21609236
Ophthalmology. 2018 Jan;125(1):57-65
pubmed: 28893454
Am J Ophthalmol. 2009 Jul;148(1):43-58.e1
pubmed: 19376495
Br J Ophthalmol. 2014 Sep;98(9):1144-67
pubmed: 25136079
Am J Ophthalmol. 2018 Mar;187:10-20
pubmed: 29269100
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT307-13
pubmed: 27409487
Ophthalmol Retina. 2018 Jan;2(1):24-30
pubmed: 31047298
Ophthalmology. 2015 Jun;122(6):1228-38
pubmed: 25795476
Retina. 2018 Feb;38(2):220-230
pubmed: 28582276
Retina. 2015 Nov;35(11):2219-28
pubmed: 26398697
Ophthalmol Retina. 2018 Sep;2(9):931-941
pubmed: 30238069
Ophthalmology. 2014 Jul;121(7):1435-44
pubmed: 24679442
Br J Ophthalmol. 2018 Jun 15;:
pubmed: 29907628
Retina. 2018 Nov;38(11):2143-2149
pubmed: 28902095
PLoS One. 2018 Oct 9;13(10):e0205513
pubmed: 30300393